About
AstraZeneca is one of the world's largest biopharmaceutical companies, created in 1999 by the merger of Sweden's Astra AB and the UK's Zeneca Group, and headquartered in Cambridge, England. The company employs about 90,000 people and generates annual revenue of roughly US$45 billion, with three therapeutic pillars: oncology, cardiovascular/renal/metabolic disease, and respiratory & immunology.\n\nAstraZeneca's oncology franchise is anchored by Tagrisso (osimertinib) for EGFR-mutated lung cancer, Imfinzi (durvalumab) for immunotherapy, and Enhertu, a breakthrough antibody-drug conjugate developed with Daiichi Sankyo that is reshaping breast-cancer treatment. The company also built a global vaccines business through the COVID-19 pandemic, developing one of the first widely deployed vaccines with the University of Oxford, and maintains manufacturing sites across the UK, Sweden, the United States, China, and Singapore.\n\nFor pharmaceutical supply chains, AstraZeneca is a major buyer of active pharmaceutical ingredients, biologics raw materials, glass vials, and packaging, with stringent GMP standards, and its global manufacturing network creates stable, long-term procurement demand for specialty chemical and life-science suppliers.
Also known as: AstraZeneca
Frequently Asked Questions
What does AstraZeneca do?+
AstraZeneca is a global biopharmaceutical company developing and selling medicines for oncology, cardiovascular, respiratory, and autoimmune diseases, as well as vaccines.
Where is AstraZeneca headquartered?+
AstraZeneca is headquartered in Cambridge, United Kingdom. It is one of the world's largest pharmaceutical companies.
What companies make up AstraZeneca?+
AstraZeneca was formed in 1999 by the merger of the British company Zeneca and the Swedish company Astra AB. It has since acquired MedImmune (2007) and Alexion (2021).
What are AstraZeneca's main products?+
Key AstraZeneca medicines include Tagrisso and Imfinzi (oncology), Farxiga (diabetes/heart failure), and its COVID-19 vaccine developed with Oxford University.
